Medical insights platform Sorcero closes $42.5M Series B

Sorcero, a downtown DC startup that makes sense of data to help patients get livesaving treatments faster, has landed $42.5 million to build its customer base and enhance user experience. 

Founded in 2018, AI-powered Sorcero pulls literature from clinical trials, PowerPoint decks, survey data and anonymized patient notes to help scientists better understand drug access and efficacy, per cofounder and CEO Dipanwita Das.

The technology, made up of proprietary algorithms, is primarily useful for medical affairs teams, i.e. the people at pharmaceutical firms who talk about their products externally. 

“Our mission as a company,” Das told Technical.ly, “is to transform lives through an effective use of the world’s scientific knowledge.”

The Series B round was led by NewSpring Capital, and joined by several existing investors including Leawood Venture Capital and Northern Virginia’s Blu Ventures. Das was looking for VCs with a deep understanding of the life sciences sector, including commercialization processes, she noted. 

Finding product-market fit = time for the next capital raise 

Das explained Sorcero originally did work across various science-driven industries — already powered by AI, even then — but in 2021 decided to go deeper in one vertical.

“It was more the shedding than the pivot,” Das said. 

The startup has in total raised $59 million in venture capital so far, through pre-seed, seed, Series A and this latest round. Das knew it was time to pool more capital, she said, because Sorcero now has firmly established product-market fit. 

The timing was also good: AI companies are dominating the venture capital market of late, accounting for 39.5% of the third quarter’s deal count this year. 

Outside of pharmaceuticals, Sorcero also works with diagnostic and medical device firms. Developing technology at the intersections of health, AI and drug adoption is becoming a hot market. For example, H1 analyzes data for people in medical affairs and commercial teams with the goal of better connecting patients to health plans that work for them.  

Strengthening customer experiences 

Furthering research and development will be a priority with these new funds, Das said, with a focus on ensuring AI safety compliance standards and laws in the US and abroad.

It’s also planning to dedicate more staff time to making sure the platform is working the way customers need and expect. Eventually, it’s considering extending the platform to be a tool in other aspects of the pharma industry, per Das. 

Expanding the client base is a goal, per Das, who said Socero currently works with 16-20 firms (she declined to name specific clients). 

About 20 people have been hired in 2025, she said, growing full-time staff to 75. Plans call for continued hiring, depending on how things go. 

“It has been growing, and it’s been growing steadily,” Das said, “but we like measured hiring, because we like to keep our people.”